Literature DB >> 25934887

Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy Efficacy via Reduction in Oxygen Demand.

Alexander Lin1, Amit Maity2.   

Abstract

Tumor hypoxia presents a unique therapeutic challenge in the treatment of solid malignancies. Its presence has been established to be a poor prognostic factor in multiple cancer types, and past hypoxia-directed approaches have yielded generally disappointing results. Previous approaches have centered on either increasing oxygen delivery or administering agents that preferentially radiosensitize or kill hypoxic cells. However, a novel and potentially more effective method may be to increase therapeutic benefit by decreasing tumor oxygen consumption via agents such as metformin or nelfinavir in a patient population that is enriched for tumor hypoxia. This promising approach is currently being investigated in clinical trials and the subject of this article. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25934887      PMCID: PMC4418024          DOI: 10.1158/1078-0432.CCR-14-0858

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  47 in total

1.  Metformin sensitizes prostate cancer cells to radiation through EGFR/p-DNA-PKCS in vitro and in vivo.

Authors:  Tingting Zhang; Long Zhang; Tao Zhang; Jinhai Fan; Kaijie Wu; Zhenfeng Guan; Xinyang Wang; Lei Li; Jer-Tsong Hsieh; Dalin He; Peng Guo
Journal:  Radiat Res       Date:  2014-05-20       Impact factor: 2.841

2.  Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer.

Authors:  A Fyles; M Milosevic; D Hedley; M Pintilie; W Levin; L Manchul; R P Hill
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

3.  Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome.

Authors:  D M Brizel; R K Dodge; R W Clough; M W Dewhirst
Journal:  Radiother Oncol       Date:  1999-11       Impact factor: 6.280

4.  Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism.

Authors:  Hélène Pelicano; Li Feng; Yan Zhou; Jennifer S Carew; Elizabeth O Hileman; William Plunkett; Michael J Keating; Peng Huang
Journal:  J Biol Chem       Date:  2003-07-09       Impact factor: 5.157

5.  Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomised trial.

Authors:  Cai Grau; Jai Prakash Agarwal; Kaukab Jabeen; Abdul Rab Khan; Sarath Abeyakoon; Tatiana Hadjieva; Ibrahim Wahid; Sedat Turkan; Hideo Tatsuzaki; Ketayun A Dinshaw; Jens Overgaard
Journal:  Radiother Oncol       Date:  2003-04       Impact factor: 6.280

6.  Reprogramming metabolism with metformin improves tumor oxygenation and radiotherapy response.

Authors:  Vanessa E Zannella; Alan Dal Pra; Hala Muaddi; Trevor D McKee; Shawn Stapleton; Jenna Sykes; Rachel Glicksman; Selim Chaib; Paul Zamiara; Michael Milosevic; Bradly G Wouters; Robert G Bristow; Marianne Koritzinsky
Journal:  Clin Cancer Res       Date:  2013-10-18       Impact factor: 12.531

7.  Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations.

Authors:  M Nordsmark; J Alsner; J Keller; O S Nielsen; O M Jensen; M R Horsman; J Overgaard
Journal:  Br J Cancer       Date:  2001-04-20       Impact factor: 7.640

8.  Regulation of O2 consumption by the PI3K and mTOR pathways contributes to tumor hypoxia.

Authors:  Catherine J Kelly; Kamila Hussien; Emmanouil Fokas; Pavitra Kannan; Rebecca J Shipley; Thomas M Ashton; Michael Stratford; Natalie Pearson; Ruth J Muschel
Journal:  Radiother Oncol       Date:  2014-03-13       Impact factor: 6.280

9.  Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK.

Authors:  Y Storozhuk; S N Hopmans; T Sanli; C Barron; E Tsiani; J-C Cutz; G Pond; J Wright; G Singh; T Tsakiridis
Journal:  Br J Cancer       Date:  2013-04-30       Impact factor: 7.640

10.  Metformin use and improved response to therapy in rectal cancer.

Authors:  Heath D Skinner; Christopher H Crane; Christopher R Garrett; Cathy Eng; George J Chang; John M Skibber; Miguel A Rodriguez-Bigas; Patrick Kelly; Vlad C Sandulache; Marc E Delclos; Sunil Krishnan; Prajnan Das
Journal:  Cancer Med       Date:  2013-02-03       Impact factor: 4.452

View more
  17 in total

Review 1.  Profiles of Radioresistance Mechanisms in Prostate Cancer.

Authors:  Luksana Chaiswing; Heidi L Weiss; Rani D Jayswal; Daret K St Clair; Natasha Kyprianou
Journal:  Crit Rev Oncog       Date:  2018

Review 2.  Repurposing Drugs for Cancer Radiotherapy: Early Successes and Emerging Opportunities.

Authors:  Mohammad K Khan; Tahseen H Nasti; Zachary S Buchwald; Ralph R Weichselbaum; Stephen J Kron
Journal:  Cancer J       Date:  2019 Mar/Apr       Impact factor: 3.360

Review 3.  Evolving Paradigms in HIV Malignancies: Review of Ongoing Clinical Trials.

Authors:  Rachel A Bender Ignacio; Lilie L Lin; Lakshmi Rajdev; Elizabeth Chiao
Journal:  J Natl Compr Canc Netw       Date:  2018-08       Impact factor: 11.908

Review 4.  Radiation oncology in the era of precision medicine.

Authors:  Michael Baumann; Mechthild Krause; Jens Overgaard; Jürgen Debus; Søren M Bentzen; Juliane Daartz; Christian Richter; Daniel Zips; Thomas Bortfeld
Journal:  Nat Rev Cancer       Date:  2016-03-18       Impact factor: 60.716

5.  The Future of Radiobiology.

Authors:  David G Kirsch; Max Diehn; Aparna H Kesarwala; Amit Maity; Meredith A Morgan; Julie K Schwarz; Robert Bristow; Sandra Demaria; Iris Eke; Robert J Griffin; Daphne Haas-Kogan; Geoff S Higgins; Alec C Kimmelman; Randall J Kimple; Isabelle M Lombaert; Li Ma; Brian Marples; Frank Pajonk; Catherine C Park; Dörthe Schaue; Phuoc T Tran; Eric J Bernhard
Journal:  J Natl Cancer Inst       Date:  2018-04-01       Impact factor: 13.506

Review 6.  Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications.

Authors:  Jacek Zielonka; Joy Joseph; Adam Sikora; Micael Hardy; Olivier Ouari; Jeannette Vasquez-Vivar; Gang Cheng; Marcos Lopez; Balaraman Kalyanaraman
Journal:  Chem Rev       Date:  2017-06-27       Impact factor: 60.622

7.  The Antiproliferative and Colony-suppressive Activities of STAT3 Inhibitors in Human Cancer Cells Is Compromised Under Hypoxic Conditions.

Authors:  Jilai Tian; Hui Xiao; Ruohan Wu; Yang Cao; Chenglong Li; Ronald Xu; Christopher R Pierson; Jonathan L Finlay; Fang Yang; Ning Gu; Jiayuh Lin
Journal:  Anticancer Res       Date:  2017-02       Impact factor: 2.480

8.  AMPK Activation and Metabolic Reprogramming by Tamoxifen through Estrogen Receptor-Independent Mechanisms Suggests New Uses for This Therapeutic Modality in Cancer Treatment.

Authors:  Natalie A Daurio; Stephen W Tuttle; Andrew J Worth; Ethan Y Song; Julianne M Davis; Nathaniel W Snyder; Ian A Blair; Constantinos Koumenis
Journal:  Cancer Res       Date:  2016-03-28       Impact factor: 12.701

9.  Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and normal tissue protection in radiotherapy.

Authors:  Jac A Nickoloff; Lynn Taylor; Neelam Sharma; Takamitsu A Kato
Journal:  Cancer Drug Resist       Date:  2021-06-19

Review 10.  Development, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1.

Authors:  Terra Arnason; Troy Harkness
Journal:  Cancers (Basel)       Date:  2015-10-16       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.